DEPOSIT AGREEMENTDeposit Agreement • March 4th, 2016 • Hutchison China MediTech LTD • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of , 2016, by and among (i) Hutchison China MediTech Limited, a company incorporated in the Cayman Islands, and its successors (the “Company”), (ii) Deutsche Bank Trust Company Americas, an indirect wholly owned subsidiary of Deutsche Bank A.G., acting in its capacity as depositary, and any successor depositary hereunder (the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares evidenced by American Depositary Receipts issued hereunder (all such capitalized terms as hereinafter defined).
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Indemnification Agreement (this “Agreement”) is made as of , 201 , by and among Hutchison China MediTech Limited, a company organized under the laws of the Cayman Islands (the “Company”), and each indemnitee executing and delivering this agreement (the “Indemnitee”).
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED English Translation SHANGHAI...Equity Joint Venture Contract • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
THIS EQUITY JOINT VENTURE CONTRACT (the “Contract”) is jointly signed in Shanghai Municipality, the People’s Republic of China (the “PRC” or “China”) on this sixth day of January 2001 by and between:
par value US$0.10 per share) UNDERWRITING AGREEMENTUnderwriting Agreement • July 2nd, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations • New York
par value US$1.00 per share) UNDERWRITING AGREEMENTUnderwriting Agreement • October 26th, 2017 • Hutchison China MediTech LTD • Pharmaceutical preparations • New York
AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT between HUTCHISON MEDIPHARMA LIMITED and ELI LILLY TRADING (SHANGHAI) COMPANY LIMITED and HUTCHISON CHINA MEDITECH LIMITEDExclusive License and Collaboration Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among (i) Hutchison MediPharma Limited, a Chinese company, organized and existing under the laws of the People’s Republic of China, having a place of business at Building 4, 720 Cai Lun Road, ZJ Hi-Tech Park, Shanghai, PRC (“Hutchison”) and (ii) Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A. (“Lilly”), and (iii) solely for the purposes of Articles 7.11(a), 7.11(b) and 7.11(c), Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (the “Hutchison Guarantor”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shal
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDED AND RESTATED...Exclusive License and Collaboration Agreement • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among (i) Hutchison MediPharma Limited, a Chinese company, organized and existing under the laws of the People’s Republic of China, having a place of business at Building 4, 720 Cai Lun Road, ZJ Hi-Tech Park, Shanghai, PRC (“Hutchison”) and (ii) Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A. (“Lilly”), and (iii) solely for the purposes of Articles 7.11(a), 7.11(b) and 7.11(c), Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (the “Hutchison Guarantor”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shal
OPTION AGREEMENT between HUTCHISON CHINA MEDITECH LIMITED and ELI LILLY AND COMPANYOption Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“Hutchison”) and Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A(“Lilly”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shall be deemed to include that Party’s Affiliates.
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED JOINT VENTURE AGREEMENT by...License Agreement • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations • England and Wales
WHEREAS, Hutchison and Nestlé have agreed to enter into a joint venture (the “Joint Venture”), subject to Antitrust Approvals, for the purpose of developing science-based personalized nutritional solutions from botanical sources for the global market. Hutchison MediPharma Limited, a limited company organized and existing under the laws of the People’s Republic of China and an Affiliate of Hutchison, has accumulated both expertise and capabilities in research and development activities in relation to identifying and developing novel naturally-derived medical foods, food supplements and drug products, in the conduct of the Hutchison Business, through the Hutchison Library and Hutchison Botanical R&D Platform (each as defined below). Under and subject to the terms of the Research and Development Collaboration Agreement (as defined below), the Company will hold exclusive rights over the Hutchison Library and the Hutchison Botanical R&D Platform in the Research Field. The Company will use t
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED English Translation FOURTH...Joint Venture Contract • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO JOINT VENTURE CONTRACT (the “Amendment No.4”) is entered into by and between the following Parties in Shanghai Municipality, China on March 8, 2013:
LICENSE AGREEMENTLicense Agreement • March 3rd, 2022 • HUTCHMED (China) LTD • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of August 7, 2021 (“Effective Date”) between Epizyme, Inc., a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 400 Technology Square, Cambridge, Massachusetts 02139 U.S. (“Epizyme”), and Hutchison China MediTech Investment Limited, a company organized and existing under the laws of the British Virgin Islands, with company number 2031179 and its registered office being Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands (“Hutchmed”). Epizyme and Hutchmed may be referred to herein individually as a “Party” and collectively as the “Parties.”
English Translation Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Equity Joint Venture Contract November 28, 2004Equity Joint Venture Contract • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
JOINT VENTURE AGREEMENT by and between HUTCHISON MEDIPHARMA (HONG KONG) LIMITED and NESTLÉ HEALTH SCIENCE S.A. and NUTRITION SCIENCE PARTNERS LIMITED and HUTCHISON CHINA MEDITECH LIMITED 27th NOVEMBER, 2012License Agreement • November 13th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations • England and Wales
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
WarrantHUTCHMED (China) LTD • August 16th, 2021 • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
English Translation THIRD AMENDMENT TO JOINT VENTURE CONTRACTJoint Venture Contract • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
THIS THIRD AMENDMENT TO JOINT VENTURE CONTRACT (the “Amendment No.3”) is entered into by and between the following Parties in Shanghai Municipality, China as of June 19, 2012:
English Translation AMENDMENT TO JOINT VENTURE CONTRACTJoint Venture Contract • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
THIS AMENDMENT TO JOINT VENTURE CONTRACT (the “Amendment”) is entered into as of July 12, 2001 in Shanghai, China by and between the following parties:
Hutchison China MediTech Limited (an exempted company incorporated in the Cayman Islands) 4,400,000 American Depositary Shares Representing 22,000,000 Ordinary Shares (par value US$0.10 per share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 23rd, 2020 • Hutchison China MediTech LTD • Pharmaceutical preparations • New York
LICENSE AND COLLABORATION AGREEMENT by and betweenLicense and Collaboration Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations • England
This LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into on this 21st day of December, 2011 (the “Effective Date”), by and among 和记黄埔医药（上海）有限公司 Hutchison Medipharma Limited, a company organized under the laws of the People’s Republic of China, having its place of business at Building 4, 720 Cailun Road, Zhangjiang Hi-Tech Park, Shanghai 201203, P.R. China (“Hutchison”) and AstraZeneca AB(publ) , a company organized under the laws of Sweden, having its place of business at S-151 85 Södertälje, Sweden (“AstraZeneca”). Hutchison and AstraZeneca may each be referred to herein individually as a “Party” and collectively as the “Parties.”
English Translation FOURTH AMENDMENT TO JOINT VENTURE CONTRACTJoint Venture Contract • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO JOINT VENTURE CONTRACT (the “Amendment No.4”) is entered into by and between the following Parties in Shanghai Municipality, China on March 8, 2013:
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED LICENSE AND COLLABORATION...License and Collaboration Agreement • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations • England
This LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into on this 21st day of December, 2011 (the “Effective Date”), by and among 和记黄埔医药（上海）有限公司 Hutchison Medipharma Limited, a company organized under the laws of the People’s Republic of China, having its place of business at Building 4, 720 Cailun Road, Zhangjiang Hi-Tech Park, Shanghai 201203, P.R. China (“Hutchison”) and AstraZeneca AB(publ) , a company organized under the laws of Sweden, having its place of business at S-151 85 Södertälje, Sweden (“AstraZeneca”). Hutchison and AstraZeneca may each be referred to herein individually as a “Party” and collectively as the “Parties.”
English Translation Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited Equity Joint Venture ContractEquity Joint Venture Contract • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
The Second Amendment to the Joint Venture Contract relating to the formation of Shanghai Hutchison Pharmaceuticals LimitedJoint Venture Contract • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
THIS SECOND AMENDMENT TO JOINT VENTURE CONTRACT (the “Amendment No.2”) is entered into by and between the following Parties in Shanghai Municipality, China on this 5th day of November 2007:
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED OPTION AGREEMENT between...Option Agreement • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“Hutchison”) and Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A(“Lilly”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shall be deemed to include that Party’s Affiliates.
FIRST AMENDMENT TO THE LICENCE AND COLLABORATION AGREEMENTLicence and Collaboration Agreement • March 13th, 2017 • Hutchison China MediTech LTD • Pharmaceutical preparations
This First Amendment (the “Amendment”) to the License and Collaboration Agreement dated December 21st 2011 (as amended) and made by and between
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDED AND RESTATED LICENSE...License and Collaboration Agreement • March 4th, 2021 • Hutchison China MediTech LTD • Pharmaceutical preparations • England
This AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into on this 7th day of December, 2020 (the “Restatement Date”), by and among 和记黄埔医药 (±海) 有限公司 Hutchison Medipharma Limited, a company organized under the laws of the People’s Republic of China, having its place of business at Building 4, 720 Cailun Road, Zhangjiang Hi-Tech Park, Shanghai 201203, P.R. China (“Hutchison”) and AstraZeneca AB(publ) , a company organized under the laws of Sweden, having its place of business at S-15 1 85 Södertälje, Sweden (“AstraZeneca”). Hutchison and AstraZeneca may each be referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT by and among HUTCHMED LIMITED (和记黄埔医药（上海）有限公司) and TAKEDA PHARMACEUTICALS INTERNATIONAL AG and HUTCHMED (CHINA) LIMITED (和黄医药（中国）有限公司) January 23, 2023License Agreement • February 28th, 2023 • HUTCHMED (China) LTD • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is entered into on this 23rd day of January, 2023 (the “Execution Date”), by and among HUTCHMED Limited (和记黄埔医药（上海）有限公司), a company organized under the laws of the People’s Republic of China, having its registered office at Building 4, 720 Cailun Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 201203, P. R. China (“HUTCHMED”), and Takeda Pharmaceuticals International AG, a company organized under the laws of Switzerland, having its principal place of business located at Thurgauerstrasse 130, 8152 Glattpark (Opfikon), Switzerland (“Company”) and, solely for the purposes of Section 11.18 (Guarantees), HUTCHMED (China) Limited (和黄医药（中国）有限公司), a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“HUTCHMED GUARANTOR”). HUTCHMED and Company may each be referred to herein individually as a “Party” and collectively as the “Parties.”
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSEDLicence and Collaboration Agreement • May 2nd, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
This First Amendment (the “ Amendment ”) to the License and Collaboration Agreement dated December 21 st 2011 (as amended) and made by and between
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED English Translation...Equity Joint Venture Contract • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
THIS EQUITY JOINT VENTURE CONTRACT (this “Contract” or the “Contract”) is jointly signed in Shanghai, the People’s Republic of China on this 18th day of December, 2013 by and between:
SECOND AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 4th, 2021 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Second Amendment (this "Second Amendment") to the Amended and Restated Exclusive License and Collaboration Agreement, effective as of October 8, 2013 and amended by the First Amendment effective as of December 18, 2018 (the "First Amendment"), and made by and between
DATED 6 August 2008Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations • England and Wales
FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • May 2nd, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
This First Amendment (this “Amendment”) to the Amended and Restated Exclusive License and Collaboration Agreement, effective as of October 8, 2013 and made by and between
HUTCHMED (CHINA) LIMITED Shares (US$0.1 par value per Share) EXEMPT OFFERING UNDERWRITING AGREEMENTExempt Offering Underwriting Agreement • June 24th, 2021 • HUTCHMED (China) LTD • Pharmaceutical preparations • New York
Shanghai Banking Corporation Limited are acting as the joint global coordinators (the Joint Global Coordinators) of the Global Offering.
DATED 15 April 2011Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations • England and Wales
AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 3rd, 2022 • HUTCHMED (China) LTD • Pharmaceutical preparations
This Amendment (the “Amendment”) to the Amended and Restated License and Collaboration Agreement dated December 7th, 2020 (collectively, the “Agreement”) and made by and between:
Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program First global pivotal Phase III in c-Met- driven papillary renal cell carcinoma (“PRCC”) to be initiated in the near futureHutchison China MediTech LTD • August 1st, 2016 • Pharmaceutical preparations
London: Monday, August 1, 2016: Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 global licensing, co-development, and commercialisation agreement (the “2011 Agreement”) regarding savolitinib. Based on data from multiple Phase I/II studies, savolitinib has shown early clinical benefit as a highly selective c-Met inhibitor in a number of cancers.
